Skuldtech becomes Acobiom
Skuldtech changed its name to Acobiom. The new name is intended to confirm the company’s strategic shift towards personalized medicine, which started in 2009 and represents a major opportunity for the medicine of the future.
Personalized medicine tailors treatment to the patient’s biological characteristics. It is one of the most promising approaches in oncology and in the targeted treatment of neurodegenerative diseases and some infections.
In taking the name Acobiom, the company seeks to promote and develop its companion diagnostics and its expertise in the discovery of new biomarkers. It also embodies their strong position within ‘omics’ technologies. In the coming months Acobiom plans to bring new companion diagnostics to market and to launch new clinical trials for cancer.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.